All News
1-Can we prevent RA ? Vagotomy?
2-CV events in auto immune rheumatic disease pregnancies.
3-CVS vasculitis , challenges and role of Brain biopsy
And others……..
https://t.co/BX8bDSX1M3
@RheumNow , daily recap
#ACR23
Nouf Al hemmadi ( View Tweet)
20 years real-world data on disease burden, patient experience & unmet needs in Refractory #RheumatoidArthritis
▶️Higher glucocorticoid & opioid use
▶️Greater comorbidity & symptom burden
▶️More rheumatology visits
#ACR23
👉🏽https://t.co/CAUorjQbvN
by @KristinWipfler @Dr_K et al https://t.co/vx1aOZizfE
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
OMG! The #Gerirheum community is looking into this bias— pls fill out their survey @UnaMakris @SattuiSEMD https://t.co/Axaoo3WohH
TheDaoIndex KDAO2011 ( View Tweet)
Automated #deeplearning systems #ArtificialIntelligence identify & predict joint damage in hand radiographs from #RheumatoidArthritis patients
➡️May aid in monitoring joint damage
#ACR23
👉🏽https://t.co/IcoZHY6lns https://t.co/mZWg6YIUp3
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
ABS0433:
⭐️Older adults w/ RA less likely to receive tx w/ DMARDs despite being well tolerated and effective
➡️Retrospect, obs using Medicare data
➡️At least 66 yo old w/ new dx of late-onset RA (LORA)
🚩If no contraindications, start DMARDs early in LORA!
#ACR23 @RheumNow https://t.co/ChalcgtS2O
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Super interesting study re: impact of ORAL SURVEILLANCE on prescribing
Post safety report, JAK pts shifted younger w/lower comorbidities (esp CVD)
I know many have mixed feelings, but I believe in the risk & support this type of shift
@RheumNow Abstr0435 #ACR23 https://t.co/EBg9VOIbj1
Mike Putman EBRheum ( View Tweet)
ABS0450
⭐️Baricitinib non-inferior as well as superior to TNFi in terms of ACR50 response @ 12w in real world csDMARD refractory RA patients
➡️open-label, T2T w/ Baricitinib (n=102) vs TNFi (n=97)
➡️DAS28-CRP remission (<0.6) in 74% of Bari vs 47% of TNFi
#ACR23 @RheumNow https://t.co/yydS20hNzM
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
ARDs increase risk for CVE in pregnancy, the highest being APS, SLE (with LN and APS) and RA. Close monitoring not only during but also after pregnancy is required. #Plenary #ACR23 https://t.co/W3CSjccSno
Adela Castro AdelaCastro222 ( View Tweet)
Phase 2 RCT of TLL-018 (JAK1/TYK2i) vs Tofa in RA. 101 patients. ACR50 72% vs 42%. 83% of tofa-IR achieved ACR50 on TLL-018. Can't wait for the phase 3 data! Abstr#0840 #ACR23 @RheumNow #ACRbest https://t.co/wjGx4Edxyb https://t.co/n6CL8G01Wo
Richard Conway ( View Tweet)
Finger fold index (FFI) calculated by deep neural network model reliable for metrical analysis and detection of swelling in RA with 91% accuracy. Mean FFI significantly higher in RA vs healthy controls PIP joints @marcblanchard23 Abst#0402 #ACR23 @RheumNow https://t.co/jmPvwzf2m8 https://t.co/DOZoV0xSsd
Dr. Antoni Chan ( View Tweet)
TLL-018, the dual JAK1/Tyk2 inhibitor which caused all the chatter at #EULAR2023, now with more full data showing it absolutely smash tofacitinib in RA, with similar safety.
“This is a spectacular compound - unbelievably spectacular” - Roy Fleischmann
#ACR23 ABST0840 @RheumNow https://t.co/nIKQb4yYrJ
David Liew drdavidliew ( View Tweet)
More on TLL-018
How?
A: Everyone surprised. But maybe dual mech benefits re: pain via IFN
Where’s the multinational RCT in RA?
A: Priority on rapid registration in China, quickly. But ph2 trials for psoriasis happening in US, results so far look consistent.
#ACR23 @RheumNow
David Liew drdavidliew ( View Tweet)
What if we deliver TNFi to the wrong place?
Delivery of ETA to peripheral lymphatics instead of subcut through a wearable device in 10pts showed:
1- is Safe
2-Reduces DAS28 (but more TJC than SJC)
To be confirmed in larger and controlled study!
@RheumNow #ACR23 ABST0838 https://t.co/IUPpFwjjbj
Aurelie Najm ( View Tweet)
Taylor et al. Positive phase 2 RCT of Nipocalimab (neonatal Fc receptor blocking monoclonal) in RA. Abstr#0839 #ACR23 @RheumNow https://t.co/UHjti200yh https://t.co/tkSlLMIl7X
Richard Conway ( View Tweet)
Ph2a Nipocalumab: FcRn blocker
IV15mg/kg TNF IR RA 32 pts
Delta DASCRP -1 vs -0.5 PBO
ACR50 20% vs 0 PBO
DAS Remission 40% vs 16% Only in ACPA+ pts
SAEs 1 infusion related reaction
Not extremely convincing alone
Currently studied in combination w/ TNFi
@RheumNow #ACR23 ABST0839 https://t.co/6wTu2ellhN
Aurelie Najm ( View Tweet)
Ross et al. Fascinating study of infusion of etanercept into lymphatics in RA in inadequate responders to s/c etanercept. DAS28(CRP) reduced 5.40±0.16 to 3.55±0.21, PGA of Disease Activity and Pain decreased by 66% and 77%. Abstr#0838 #ACR23 @RheumNow https://t.co/RIMCS3nmy6 https://t.co/U2689atvmj
Richard Conway ( View Tweet)
APIPPRA trial of abatacept to prevent RA in sero+ arthralgia. Picture paints a thousand words - big difference at week 52 (on abatacept) and watch those lines converge Abstr#0835 #ACR23 #ACRbest @RheumNow https://t.co/cwX389TUZN https://t.co/2CQHYlW0nq
Richard Conway ( View Tweet)
Baker et al. Danish registry study. Truncal vagotomy increases risk RA (but not OA), HR 2.62 (95% CI 1.47-4.67). Support for vagus nerve stimulation in RA? Abstr#0836 #ACR23 @RheumNow https://t.co/SbphSMLHc7 https://t.co/93SfyGizLt
Richard Conway ( View Tweet)
Inflammatory reflex suggests role of vagal nerve in inflammation regulation
Danish database
Truncal vagotomy
2000+ pts matched w/ 22000+ = Increase risk for RA HR 2.6
Not the case for supras elective vagotomy (HR 1)
No influence on OA
@RheumNow #ACR23 ABST0836 https://t.co/3ThYP1nKTe
Aurelie Najm ( View Tweet)
Here's the counterpoint to the previous positive tweet on vagal nerve stimulation in RA. The previously promising data on auricular vagus stimulation falls flat on further study Abstr#0837 #ACR23 @RheumNow https://t.co/APnrPhWA9q https://t.co/adA0H1VETt
Richard Conway ( View Tweet)
